Company: CERO
Filing Date: 2025-01-06
Form Type: 8-K
Source: 0001213900-25-001156
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-06
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On January 6, 2025, the Company issued a press
release announcing the Reverse Stock Split and other related information. A copy of the press release is furnished herewith as Exhibit
99.1 to this Current Report on Form 8-K.

Cautionary Note Regarding Forward Looking Statements

This communication contains
statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the
Company’s expectations about the effects of the Reverse Stock Split, including the trading of the Company’s common stock on
The Nasdaq Global Market following the Reverse Stock Split. These statements constitute projections, forecasts and forward-looking statements,
and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or
current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “strive,”
“would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that
a statement is not forward-looking. When the Company discusses its strategies or plans, it is making projections, forecasts or forward-looking
statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, the Company’s
management.

Actual results could differ
from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ include,
among others: outcomes of the Company’s planned clinical trials and studies may not be favorable; that one or more of the Company’s
product candidate programs will not proceed as planned for technical, scientific or commercial reasons; availability and timing of results
from preclinical studies and clinical trials; uncertainty about regulatory approval to conduct clinical trials or to market a products;
uncertainties regarding intellection property protection; and those set forth in the Company’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The
risks described in the Company’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge
from time to time, and it is not possible to predict all such risk factors, nor can the Company assess